# An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

> **NCT07076446** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **CSL Behring** · enrollment: 8 (actual)

## Conditions studied

- Primary Immunodeficiency

## Interventions

- **BIOLOGICAL:** IgPro

## Key facts

- **NCT ID:** NCT07076446
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07076446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07076446, "An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07076446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*